Member

Revolution Biomanufacturing Inc.


Revolution Biomanufacturing Inc. (RBIx) is expanding beyond traditional CDMO Process/Analytical Development and Manufacturing services to pioneer distributed molecular manufacturing. A new class of digital biomanufacturing that enables the autonomous design, manufacture, quality verification, and deployment of Nucleic Acid therapeutics and molecular diagnostics at the point of need. By integrating AI-driven sequence optimization, enzymatic nucleic acid synthesis, Nanoparticle design and manufacturing (LNP & EV), closed-loop quality control, and field-deployable manufacturing platforms, RBIx is creating adaptive biological infrastructure capable of responding to emerging diseases, national security threats, and personalized medicine with unprecedented speed and flexibility.

Industries

Biotechnology
Pharmaceutical Manufacturing
Contract Research Organization
Nano Technology (Lipid Nanoparticles LNP and Extracellular Vesical).
Drug Substance Development and Manufacturing
Drug Product Development and Manufacturing
Research Use Material Development and Manufacturing
Adaptive, Autonomous, and Distributed Molecular Readiness

Nr. of Employees

small (1-50)

Revolution Biomanufacturing Inc.

Revolution Biomanufacturing Inc. is currently seeking investment

Revolution Biomanufacturing Inc. is seeking a series-a investment in the range of 20m-50m

All Investment-seeking Members

Products

RevSelect™

AI-Driven Sequence Optimization Platform 5' UTR optimization 3' UTR optimization Codon optimization Translation efficiency prediction RNA stability optimization Manufacturability optimization Cell-specific expression optimization AI assay design Design-for-manufacturing algorithms Applications: mRNA saRNA circRNA DNA templates PCR primers Diagnostic probes CRISPR guides

RevSolve™

AI Design-to-Manufacture Platform Automated process development Digital batch records Manufacturing optimization Closed-loop process control Predictive process analytics Electronic release AI manufacturing assistant

RevLoop™

Circular RNA Platform Patent-pending circularization Manufacturing process Stabilization technology Immune-silent constructs High-expression circRNA

RevTarget™

Targeted Lipid Platform AI lipid selection and patent-pending lipid library Organ targeting Cell and Tissue targeting Protein corona engineering Passive targeting Active targeting through Drug Conjugation Antibody-directed LNPs Applications Liver Lung Spleen T cells B cells CAR-T Gene editing Lyophilized LNP Technology Shelf-stable LNP Cold-chain reduction Pandemic stockpiling Military deployment

SwiftScale™

Distributed Mobile RNA Manufacturing Units Modular GMP Rapid deployment Military Disaster response Regional manufacturing

Cell & Gene Therapy

CAR-T In vivo CAR Gene editing CRISPR support mRNA delivery DNA template production

View All Products

Services

Design and optimization of mRNA products, DNA templates, and process development for biologics including stability and translation efficiency improvements. Upstream IVT Downstream purification TFF optimization Oligo-dT purification Sterile filtration Process characterization Scale-up Technology transfer

Encapsulation of mRNA and other therapeutics with advanced lipid nanoparticles for improved delivery and bioavailability.

Scalable, regulatory-compliant production and fill-finish of mRNA drug substances and therapeutics.

Guidance and management for IND/BLA submissions, regulatory gap assessments, and oversight of outsourced development projects.

Analytical Development

PCR assays RT-PCR assays CRISPR diagnostics LAMP assays RPA assays VT analytics mRNA characterization dsRNA analysis Cap analysis Poly(A) analysis Fragment analysis LNP characterization Encapsulation efficiency Potency assays Stability studies IND analytical packages

Circular RNA Platform

Manufacturing process Stabilization technology Immune-silent constructs High-expression circRNA

View All Services

Expertise Areas

  • mRNA and Nucleic Acid therapeutics bioprocessing
  • Personalized medicine manufacturing
  • Distributed and closed loop manufacturing
  • Regulatory compliance (IND, NDA, BLA)
  • Show More (4)

Key Technologies

  • In vitro transcription (IVT)
  • Lipid nanoparticle formulation
  • Custom DNA template engineering
  • Mammalian and microbial cell culture
  • Show More (3)

Key People

Molly S. McGlaughlin, MS, MeD

CEO

LinkedIn

Jenny Zhao, MEng

VP, Operations

Changyuan Lu, PhD

Director, Nanotechnology and Drug Product Innovation

Manika Bhondeley, PhD

Director, Nucleic Acid Innovation


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.